1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is 39,90€ (+3.736,54%). The median is 4,29€ (+312,50%).
| Buy |
4 |
| Hold |
3 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 7,16M | 25,33% |
| Gross profit | 3,78M | 28,14% |
| Net profit | −6,50M | 11,80% |
| EBITDA | −4,49M | 18,96% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 12,01M€ |
Number of shares | 11,48M |
52-week high/low | 4,72€ - 0,86€ |
| Dividends | No |
Beta | 1,62 |
P/E ratio | −0,33 |
PEG ratio | 0,00 |
P/B ratio | 0,45 |
P/S ratio | 0,46 |
Company profile
| Name | Bionano Genomics |
| CEO | Albert A. Luderer |
| Headquarters | San Diego,
ca USA |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| Employees | 96 |
Discover assets
Shareholders of Bionano Genomics also invest in the following assets
